Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction

Circulation: Heart Failure

Volumn 4, Issue 5, 2011, Pages 578-588

  Wessler, Benjamin S ^a   Kramer, Daniel G ^a   Kelly, Jessica L ^a   Trikalinos, Thomas A ^a   Kent, David M ^a   Konstam, Marvin A ^a   Udelson, James E ^a  

^a Institute for Clinical Research and Health Policy Studies   (United States)

Author keywords

6 minute walk; Biomarkers; Meta analysis; Peak Vo 2; Systolic heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PLACEBO; BIOLOGICAL MARKER; NATRIURETIC FACTOR;

ARTICLE; DEVICE THERAPY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MORTALITY; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIX MINUTE WALK DISTANCE; SYSTEMATIC REVIEW; THERAPY EFFECT; WALKING; BLOOD; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART STROKE VOLUME; MALE; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; OXYGEN CONSUMPTION; PREDICTIVE VALUE OF TESTS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84856389817     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.961573     Document Type: Article

References (128)

1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-1402. (Pubitemid 35239711)
2. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (renewal). Circulation. 2004;109:1594-1602. (Pubitemid 38451714)
3. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (overture). Circulation. 2002;106:920-926. (Pubitemid 34925324)
4. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: Impress randomised trial. Lancet. 2000;356:615-620. (Pubitemid 30627587)
5. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelina receptor antagonist trial in heart failure (earth): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347-354. (Pubitemid 38970011)
6. Kalra PR, Moon JC, Coats AJ. Do results of the enable (endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85:195-197. (Pubitemid 35245980)
7. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol. 2002;39:1414-1421. (Pubitemid 34439054)
8. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a metaanalytic approach. J Am Coll Cardiol. 2010;56:392-406.
9. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-786.
10. Szlachcic J, Massie BM, Kramer BL, Topic N, Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol. 1985;55:1037-1042. (Pubitemid 15085359)
11. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 1987;59:634-638. (Pubitemid 17047334)
12. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. the V-HeFT VA cooperative studies group. Circulation. 1993;87:VI5-V16.
13. Enright PL. The six-minute walk test. Respir Care. 2003;48:783-785. (Pubitemid 47377828)
14. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919-923.
15. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M, Greenberg B, Woods PA, Bourassa MG. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction: SOLVD investigators. JAMA. 1993;270:1702-1707. (Pubitemid 23295315)
16. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-391.
17. Richards AM, Nicholls MG, Yandle TG, Ikram H, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Frampton C, Crozier IG, Smyth DW. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction: the Christchurch Cardioendocrine Research Group. Heart. 1999;81:114-120. (Pubitemid 29119383)
18. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: Consensus trial study group. Circulation. 1990;82:1730-1736. (Pubitemid 20367976)
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
20. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
21. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-826. (Pubitemid 27465551)
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558. (Pubitemid 34746062)
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. (Pubitemid 37088507)
24. Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80.
25. Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O'Connor CM, Weinfurt KP. Effects of exercise training on health status in patients with chronic heart failure: HF-Action randomized controlled trial. JAMA. 2009;301:1451-1459.
26. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, Keren A, Motro M, Moye LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleau JL, Sestier F, Winkelmann BR, Young JB. Results of a non-specific immunomodulation therapy in chronic heart failure (acclaim trial): a placebo-controlled randomised trial. Lancet. 2008;371:228-236.
27. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261. (Pubitemid 350190755)
28. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:304-310. (Pubitemid 34756292)
29. Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, Cattadori G, Palermo P. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J. 2005;26:159-164. (Pubitemid 40282784)
30. Agostoni P, Guazzi M, Bussotti M, De Vita S, Palermo P. Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients. Chest. 2002;122:2062-2067. (Pubitemid 36054183)
31. Guazzi M, Agostoni P, Matturri M, Pontone G, Guazzi MD. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J. 1999;138:460-467. (Pubitemid 29428768)
32. Agostoni P, Contini M, Magini A, Apostolo A, Cattadori G, Bussotti M, Veglia F, Andreini D, Palermo P. Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia. Eur J Heart Fail. 2006;8:729-735. (Pubitemid 44637272)
33. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, De Long G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499-1506.
34. Dubach P, Myers J, Bonetti P, Schertler T, Froelicher V, Wagner D, Scheidegger M, Stuber M, Luchinger R, Schwitter J, Hess O. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J. 2002;143:676-683. (Pubitemid 34454701)
35. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536-546. (Pubitemid 15242247)
36. Gullestad L, Manhenke C, Aarsland T, Skardal R, Fagertun H, Wikstrand J, Kjekshus J. Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure: a substudy to the Merit-HF trial. Eur J Heart Fail. 2001;3:463-468. (Pubitemid 32776873)
37. Genth-Zotz S, Zotz RJ, Sigmund M, Hanrath P, Hartmann D, Bohm M, Waagstein F, Treese N, Meyer J, Darius H. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. Eur J Heart Fail. 2000;2:175-181. (Pubitemid 30407558)
38. de Milliano PA, de Groot AC, Tijssen JG, van Eck-Smit BL, Van Zwieten PA, Lie KI. Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J. 2002;144:E3.
39. Beshai JF, Grimm RA, Nagueh SF, Baker JH II, Beau SL, Greenberg SM, Pires LA, Tchou PJ. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007;357:2461-2471. (Pubitemid 350272785)
40. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, Lieberman R, Liem LB, O'Connell JB, Schroeder JS, Wheelan KR. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter- defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864-2868. (Pubitemid 39473610)
41. De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbotham MB, Ghali JK, Wagoner L, Kirlin PC, Kennett JD, Goel S, Saxon LA, Boehmer JP, Mann D, Galle E, Ecklund F, Yong P, Bristow MR. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: companion trial sub-study. J Card Fail. 2008;14:9-18.
42. Auricchio A, Kloss M, Trautmann SI, Rodner S, Klein H. Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. Am J Cardiol. 2002;89:198-203. (Pubitemid 34132910)
43. Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, Bocker D, Block M, Kirkels JH, Kramer A, Huvelle E. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol. 2003;42:2109-2116. (Pubitemid 37549894)
44. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the Miracle ICD trial. JAMA. 2003;289:2685-2694. (Pubitemid 37430139)
45. Piepoli MF, Villani GQ, Corra U, Aschieri D, Rusticali G. Time course of effects of cardiac resynchronization therapy in chronic heart failure: benefits in patients with preserved exercise capacity. Pacing Clin Electrophysiol. 2008;31:701-708. (Pubitemid 351749312)
46. Braun MU, Rauwolf T, Zerm T, Schulze M, Schnabel A, Strasser RH. Long-term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones. Heart. 2005;91:601-605. (Pubitemid 40559348)
47. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, Higginbotham MB, De Marco T, Foster E, Yong PG. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454-1459. (Pubitemid 37267289)
48. Ziesche S, Cobb FR, Cohn JN, Johnson G, Tristani F. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure: results from V-HeFT I and V-HeFT II: the V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI56-VI64. (Pubitemid 23164223)
49. 2 ratio in myocardial infarction patients with low ejection fraction. Chest. 1998;114:1289-1294. (Pubitemid 28527400)
50. Cocchieri M, Alunni GF, Del Favero A, Fortunati F, Bardelli G, Capponi EA, Regi L, Boschetti E. Comparative effects of ibopamine and captopril in mild congestive heart failure: focus on the long-term effects of inodilation on ventricular arrhythmias. Cardiology. 1990;77(Suppl 5):36-42. (Pubitemid 20385943)
51. Ellis GR, Nightingale AK, Blackman DJ, Anderson RA, Mumford C, Timmins G, Lang D, Jackson SK, Penney MD, Lewis MJ, Frenneaux MP, Morris-Thurgood J. Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. Eur J Heart Fail. 2002;4:193-199. (Pubitemid 34233507)
52. Guazzi M, Palermo P, Pontone G, Susini F, Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol. 1999;84:1038-1043. (Pubitemid 29505372)
53. Dickstein K, Barvik S, Aarsland T. Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarction. J Am Coll Cardiol. 1991;18:596-602.
54. Gottlieb SS, Fisher ML, Freudenberger R, Robinson S, Zietowski G, Alves L, Krichten C, Vaitkevicus P, McCarter R. Effects of exercise training on peak performance and quality of life in congestive heart failure patients. J Card Fail. 1999;5:188-194. (Pubitemid 29449256)
55. Kiilavuori K, Sovijarvi A, Naveri H, Ikonen T, Leinonen H. Effect of physical training on exercise capacity and gas exchange in patients with chronic heart failure. Chest. 1996;110:985-991. (Pubitemid 26347614)
56. Wielenga RP, Huisveld IA, Bol E, Dunselman PH, Erdman RA, Baselier MR, Mosterd WL. Safety and effects of physical training in chronic heart failure: results of the chronic heart failure and graded exercise study (change). Eur Heart J. 1999;20:872-879. (Pubitemid 29253733)
57. Wielenga RP, Erdman RA, Huisveld IA, Bol E, Dunselman PH, Baselier MR, Mosterd WL. Effect of exercise training on quality of life in patients with chronic heart failure. J Psychosom Res. 1998;45:459-464. (Pubitemid 28499992)
58. Tyni-Lenne R, Gordon A, Jansson E, Bermann G, Sylven C. Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997;80:1025-1029. (Pubitemid 27459202)
59. Sturm B, Quittan M, Wiesinger GF, Stanek B, Frey B, Pacher R. Moderate-intensity exercise training with elements of step aerobics in patients with severe chronic heart failure. Arch Phys Med Rehabil. 1999;80:746-750. (Pubitemid 29320968)
60. Keteyian SJ, Levine AB, Brawner CA, Kataoka T, Rogers FJ, Schairer JR, Stein PD, Levine TB, Goldstein S. Exercise training in patients with heart failure: a randomized, controlled trial. Ann Intern Med. 1996;124:1051-1057.
61. Keteyian SJ, Brawner CA, Schairer JR, Levine TB, Levine AB, Rogers FJ, Goldstein S. Effects of exercise training on chronotropic incompetence in patients with heart failure. Am Heart J. 1999;138:233-240. (Pubitemid 29379672)
62. Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, Schoene N, Schuler G. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA. 2000;283:3095-3101. (Pubitemid 30399720)
63. Hambrecht R, Niebauer J, Fiehn E, Kalberer B, Offner B, Hauer K, Riede U, Schlierf G, Kubler W, Schuler G. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol. 1995;25:1239-1249.
64. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999;99:1173-1182. (Pubitemid 29120089)
65. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Effects of exercise training on left ventricular filling at rest and during exercise in patients with ischemic cardiomyopathy and severe left ventricular systolic dysfunction. Am Heart J. 1996;132:61-70. (Pubitemid 26243693)
66. Belardinelli R, Georgiou D, Cianci G, Berman N, Ginzton L, Purcaro A. Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy: clinical and prognostic implications. Circulation. 1995;91:2775-2784.
67. Maria Sarullo F, Gristina T, Brusca I, Milia S, Raimondi R, Sajeva M, Maria La Chiusa S, Serio G, Paterna S, Di Pasquale P, Castello A. Effect of physical training on exercise capacity, gas exchange and n-terminal pro-brain natriuretic peptide levels in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2006;13:812-817. (Pubitemid 44454856)
68. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998;98:2709-2715. (Pubitemid 28564006)
69. Uretsky BF, Jessup M, Konstam MA, Dec. GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo: Enoximone multicenter trial group. Circulation. 1990;82:774-780. (Pubitemid 20316728)
70. Walsh JT, Andrews R, Curtis S, Evans A, Cowley AJ. Effects of amlodipine in patients with chronic heart failure. Am Heart J. 1997;134:872-878. (Pubitemid 27522992)
71. Fleg JL, Rothfeld B, Gottlieb SH. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 1991;17:743-751.
72. Dunselman PH, Kuntze CE, van Bruggen A, Hamer JP, Scaf AH, Wessling H, Lie KI. Efficacy of felodipine in congestive heart failure. Eur Heart J. 1989;10:354-364. (Pubitemid 19118988)
73. Levine TB, Bernink PJ, Caspi A, Elkayam U, Geltman EM, Greenberg B, McKenna WJ, Ghali JK, Giles TD, Marmor A, Reisin LH, Ammon S, Lindberg E. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study: mortality assessment in congestive heart failure trial. Circulation. 2000;101:758-764. (Pubitemid 30100082)
74. Szabo BM, van Veldhuisen DJ, van der Burgh PH, Kruik J, Girbes AR, Lie KI. Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. J Card Fail. 1996;2:185-192.
75. Dei Cas L, Metra M, Visioli O. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. Am J Cardiol. 1992;70:629-634.
76. Elborn JS, Stanford CF, Nicholls DP. Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Br Heart J. 1989;61:331-335. (Pubitemid 19105197)
77. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure: principal investigators of the reflect study. J Am Coll Cardiol. 1993;22:65-72. (Pubitemid 23189936)
78. Haas GJ, Binkley PE, Leier CV. Chronic vasodilator therapy with flosequinan in congestive heart failure. Clin Cardiol. 1990;13:414-420. (Pubitemid 20178731)
79. Hori M, Sato H, Ozaki H, Inoue M, Naka M, Fukunami M, Fukushima M, Kunisada K. Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study. Heart Vessels. 1992;7:133-140.
80. Banning AP, Ramsey MW, Jones EA, Evans W, Carolan G, Jones CH, Henderson AH. Flosequinan in chronic heart failure: how is exercise capacity improved? Eur J Clin Pharmacol. 1996;51:133-138. (Pubitemid 26342768)
81. Likoff MJ, Weber KT, Andrews V, Janicki JS, Wilson H, Rocci ML Jr. Milrinone in the treatment of chronic cardiac failure: a controlled trial. Am Heart J. 1985;110:1035-1042. (Pubitemid 16052597)
82. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD pilot study investigators. Circulation. 1999;100:1056-1064. (Pubitemid 29416231)
83. Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, Held P, Michelson EL, Sellers MA, Ohlin G, Sparapani R, Pfeffer MA. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139:609-617. (Pubitemid 30207785)
84. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P. Doseresponse of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol investigators. Circulation. 1994;89:1632-1642. (Pubitemid 24114241)
85. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42:1944-1951. (Pubitemid 37485570)
86. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure: the US Carvedilol Heart Failure Study Group. J Card Fail. 1997;3:173-179. (Pubitemid 127674849)
87. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation. 1996;94:2807-2816. (Pubitemid 26411745)
88. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, Le Jemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebocontrolled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial: Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation. 1996;94:2793-2799. (Pubitemid 26411743)
89. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure: US Carvedilol Heart Failure Study Group. Circulation. 1996;94:2800-2806. (Pubitemid 26411744)
90. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-880. (Pubitemid 32224395)
91. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853. (Pubitemid 34603028)
92. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, Di Carlo L, De Mets D, White BG, De Vries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
93. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 2000;101:378-384.
94. Sanderson JE, Chan SK, Yu CM, Yeung LY, Chan WM, Raymond K, Chan KW, Woo KS. Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. Heart. 1998;79:86-92. (Pubitemid 28179071)
95. Beanlands RS, Nahmias C, Gordon E, Coates G, de Kemp R, Firnau G, Fallen E. The effects of beta (1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation. 2000;102:2070-2075.
96. Prescott E, Hjardem-Hansen R, Dela F, Orkild B, Teisner AS, Nielsen H. Effects of a 14-month low-cost maintenance training program in patients with chronic systolic heart failure: a randomized study. Eur J Cardiovasc Prev Rehabil. 2009;16:430-437.
97. Dracup K, Evangelista LS, Hamilton MA, Erickson V, Hage A, Moriguchi J, Canary C, MacLellan WR, Fonarow GC. Effects of a home-based exercise program on clinical outcomes in heart failure. Am Heart J. 2007;154:877-883. (Pubitemid 47632497)
98. Evangelista LS, Doering LV, Lennie T, Moser DK, Hamilton MA, Fonarow GC, Dracup K. Usefulness of a home-based exercise program for overweight and obese patients with advanced heart failure. Am J Cardiol. 2006;97:886-890.
99. van den Berg-Emons R, Balk A, Bussmann H, Stam H. Does aerobic training lead to a more active lifestyle and improved quality of life in patients with chronic heart failure? Eur J Heart Fail. 2004;6:95-100. (Pubitemid 38169610)
100. Corvera-Tindel T, Doering LV, Woo MA, Khan S, Dracup K. Effects of a home walking exercise program on functional status and symptoms in heart failure. Am Heart J. 2004;147:339-346. (Pubitemid 38176836)
101. Giannuzzi P, Temporelli PL, Corra U, Tavazzi L. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) trial. Circulation. 2003;108:554-559. (Pubitemid 36961169)
102. Kobayashi N, Tsuruya Y, Iwasawa T, Ikeda N, Hashimoto S, Yasu T, Ueba H, Kubo N, Fujii M, Kawakami M, Saito M. Exercise training in patients with chronic heart failure improves endothelial function predominantly in the trained extremities. Circ J. 2003;67:505-510. (Pubitemid 36702058)
103. McKelvie RS, Teo KK, Roberts R, McCartney N, Humen D, Montague T, Hendrican K, Yusuf S. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J. 2002;144:23-30. (Pubitemid 34734751)
104. Guyatt GH, Sullivan MJ, Fallen EL, Tihal H, Rideout E, Halcrow S, Nogradi S, Townsend M, Taylor DW. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988;61:371-375.
105. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial: PROVED Investigative Group. J Am Coll Cardiol. 1993;22:955-962. (Pubitemid 23285742)
106. Udelson JE, De Abate CA, Berk M, Neuberg G, Packer M, Vijay NK, Gorwitt J, Smith WB, Kukin ML, Le Jemtel T, Levine TB, Konstam MA. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J. 2000;139:503-510. (Pubitemid 30149201)
107. Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 2010;133:14-23.
108. Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O. Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol. 2010;99:445-452.
109. Berry C, Murphy NF, De Vito G, Galloway S, Seed A, Fisher C, Sattar N, Vallance P, Hillis WS, McMurray J. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a betablocker. Eur J Heart Fail. 2007;9:429-434. (Pubitemid 46441973)
110. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228-1233.
111. Rousseau MF, Gurne O, Duprez D, Van Mieghem W, Robert A, Ahn S, Galanti L, Ketelslegers JM. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES Neurohormonal Substudy. J Am Coll Cardiol. 2002;40:1596-1601. (Pubitemid 35253637)
112. Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med. 2007;48:1993-2000. (Pubitemid 350232308)
113. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation. 2006;113:977-985. (Pubitemid 43879473)
114. Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a welltreated black population with heart failure: results from A-Heft. J Card Fail. 2007;13:331-339. (Pubitemid 46978420)
115. Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A. Double-blind, randomized, placebo-controlled study of high-dose HMG coA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail. 2007;13:1-7. (Pubitemid 46330836)
116. Wijeysundera HC, Hansen MS, Stanton E, Cropp AS, Hall C, Dhalla NS, Ghali J, Rouleau JL. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J. 2003;146:291-297. (Pubitemid 36951774)
117. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Trawinski J, Amann-Zalan I, Hoersch S, Katus HA. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the Copernicus NT-proBNP substudy. Eur J Heart Fail. 2004;6:343-350. (Pubitemid 38253055)
118. Cleland J, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M, Verboven Y, Tavazzi L. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. J Am Coll Cardiol. 2008;52:438-445. (Pubitemid 352040815)
119. Hoijer CJ, Meurling C, Brandt J. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double-blind, randomized crossover study. Europace. 2006;8:51-55.
120. White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R. Effects of combined candesartan and ace inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail. 2007;13:86-94. (Pubitemid 46467388)
121. Sugiura T, Takase H, Toriyama T, Goto T, Ueda R, Dohi Y. Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail. 2005;11:504-509. (Pubitemid 41399889)
122. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49:1943-1950. (Pubitemid 46694287)
123. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Di Bianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, De Mets DL. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
124. Elborn JS, Stanford CF, Nicholls DP. Reproducibility of cardiopulmonary parameters during exercise in patients with chronic cardiac failure: the need for a preliminary test. Eur Heart J. 1990;11:75-81. (Pubitemid 20042310)
125. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. Thorax. 1984;39:818-822. (Pubitemid 14022730)
126. Middlekauff HR. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail. 2010;3:537-546.
127. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J. 1998;136:449-457. (Pubitemid 28413542)
128. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006;333:597-600. (Pubitemid 44433638)